Researchers analyzed the health records of more than 33,800 U.S. veterans diagnosed with non-melanoma skin cancer and found ...
The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...
This news could be tough to face. A new report from the Skin Cancer Foundation predicts that 234,680 cases of melanoma will ...
Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...
A recent study revealed that commonly used over-the-counter vitamin B3 supplements may keep you protected from specific types ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
Receiving a diagnosis of squamous cell carcinoma (SCC) can be an overwhelming experience, but it is important to remember that you are not alone. SCC is one of the most common forms of skin cancer ...
Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...
What if the earliest signs of skin cancer could be identified sooner—before a dermatology appointment?
Jan 20 () - Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results